Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Submits Plan to Regain NYSE Compliance

NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has submitted a plan to the New York Stock Exchange's Alternext market for regaining compliance with the exchange's continued listing requirements.

The Waltham, Mass.-based firm announced at the end of December that it had received a letter for the Alternext saying that it was not in compliance with certain listing criteria. Specifically, the firm's stockholders' equity is less than $6 million and it has reported losses from continuing operations and net losses in its five most recent fiscal years.

Interleukin said that it expects the exchange to formally respond to its plan within 45 days. If the plan is expected, Interleukin would continue to float on the exchange up to June 23, 2010, and would be subject to periodic review. If the plan is not accepted, it would have the right to appeal the decision.

Filed under

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.